Extrinsic hemolytic normocytic anemia: Pathology review

13,178views

Extrinsic hemolytic normocytic anemia: Pathology review

Back to the Basic Sciences

Acutely ill child

Acyanotic congenital heart defects: Pathology review
Adrenal masses: Pathology review
Bacterial and viral skin infections: Pathology review
Bone tumors: Pathology review
Coagulation disorders: Pathology review
Congenital neurological disorders: Pathology review
Cyanotic congenital heart defects: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Headaches: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Leukemias: Pathology review
Lymphomas: Pathology review
Macrocytic anemia: Pathology review
Microcytic anemia: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Nasal, oral and pharyngeal diseases: Pathology review
Nephritic syndromes: Pathology review
Nephrotic syndromes: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Pediatric brain tumors: Pathology review
Pediatric musculoskeletal disorders: Pathology review
Platelet disorders: Pathology review
Renal and urinary tract masses: Pathology review
Seizures: Pathology review
Viral exanthems of childhood: Pathology review
Antidiuretic hormone
Body fluid compartments
Movement of water between body compartments
Sodium homeostasis
Acid-base disturbances: Pathology review
Diabetes insipidus and SIADH: Pathology review
Electrolyte disturbances: Pathology review
Renal failure: Pathology review
Central nervous system infections: Pathology review
Congenital TORCH infections: Pathology review
Jaundice: Pathology review
Respiratory distress syndrome: Pathology review
Adrenal insufficiency: Pathology review
Central nervous system infections: Pathology review
Childhood and early-onset psychological disorders: Pathology review
Congenital gastrointestinal disorders: Pathology review
Diabetes mellitus: Pathology review
Electrolyte disturbances: Pathology review
Environmental and chemical toxicities: Pathology review
Gastrointestinal bleeding: Pathology review
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Inflammatory bowel disease: Pathology review
Medication overdoses and toxicities: Pathology review
Obstructive lung diseases: Pathology review
Pediatric brain tumors: Pathology review
Pediatric musculoskeletal disorders: Pathology review
Pneumonia: Pathology review
Psychiatric emergencies: Pathology review
Seizures: Pathology review
Shock: Pathology review
Supraventricular arrhythmias: Pathology review
Traumatic brain injury: Pathology review
Ventricular arrhythmias: Pathology review

Therapeutics

Androgens and antiandrogens
Estrogens and antiestrogens
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Antihistamines for allergies
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Glucocorticoids
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Azoles
Glucocorticoids
Pulmonary corticosteroids and mast cell inhibitors
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antimetabolites: Sulfonamides and trimethoprim
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Drug-receptor interactions
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug metabolism
Cell wall synthesis inhibitors: Cephalosporins
Glucocorticoids
Miscellaneous protein synthesis inhibitors
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Miscellaneous cell wall synthesis inhibitors

Transcript

Watch video only

At the family medicine center, two people came in with progressive fatigue.

One of them is a 60 years old named Will whose past medical history included an aortic valve replacement with a mechanical valve due to severe aortic stenosis.

There’s Hanna, a 28 years old female of African descent.

She was diagnosed a year ago with systemic lupus erythematosus, or SLE. CBC is ordered for both people and it shows low hemoglobin with normal mean corpuscular volume, or MCV and reticulocyte count index over 2%.

They also have increased LDH. Now, Will has schistocytes on peripheral blood smear, while Hanna has spherocytes.

Both Will and Hannah are suffering from anemia, which is defined as lower than average levels of hemoglobin, typically below 13.5 g/dL in adult men and below 12.0 g/dL in adult women.

For children, this level varies based on the age. Now, anemias can be broadly grouped into 3 categories based on =MCV, which reflects the volume of an RBC.

So microcytic anemia is where the MCV is lower than 80 fL, normocytic, with an MCV between 80 and 100 fL, and macrocytic, with an MCV larger than 100 fL.

Normocytic anemias can be further classified as hemolytic when there’s increased destruction of RBCs, or hemolysis, and non-hemolytic when there’s decreased production of RBCs from the bone marrow.

When there’s hemolysis, the bone marrow revs up and starts pumping out immature RBCs called reticulocytes, but when there’s a bone marrow problem reticulocyte count is low.

So for your exams, it’s important to know that in hemolytic anemias there’s an increased reticulocyte production index of over 2%, while in non-hemolytic anemias it’s lower than 2%.

Alright, now hemolytic anemias can be classified as intrinsic or extrinsic hemolytic anemias.

In intrinsic hemolytic anemias, RBCs are destroyed because they’re defective, while in extrinsic hemolytic anemias, RBCs are normal but are later destroyed outside the bone marrow.

In this video, let’s focus on extrinsic hemolytic anemias that include autoimmune hemolytic anemia, microangiopathic hemolytic anemia, macroangiopathic hemolytic anemia and infections.

Now, we can divide extrinsic hemolysis into intravascular, meaning RBCs are destroyed within the vasculature, or extravascular, meaning that they are removed by macrophages in the spleen and liver.

Microangiopathic and macroangiopathic hemolytic anemias are intravascular, autoimmune hemolytic anemia is usually extravascular, while infections can cause both intravascular and extravascular.

There are findings that can help identify the type of hemolysis. In intravascular hemolysis, hemoglobin that is released inside the vessels gets bound by a protein called haptoglobin and because they’re removed together, haptoglobin decreases.

Also, when haptoglobin gets overwhelmed, the rest of hemoglobin goes via the blood through the kidneys and into the urine resulting in hemoglobinuria.

Now, when hemoglobin is inside the renal tubules, the cells lining the renal tubules reabsorb hemoglobin.

The heme component of hemoglobin contains iron which is stored as hemosiderin in tubular cells and after a few days, when tubular cells slough into urine, there’s hemosiderinuria. Hemoglobinuria and hemosiderinuria can damage the kidneys causing back pain.

Okay, now in extravascular hemolysis, RBCs are destroyed outside the vessels and so, haptoglobin is normal and there’s no hemoglobin or hemosiderin in the urine.

RBCs are usually destroyed in the spleen causing splenomegaly or the liver causing hepatomegaly.

Alright, now whenever there’s RBC lysis, an intracellular enzyme called lactate dehydrogenase, or LDH, spills out directly into the plasma and builds up in the blood.

Hemoglobin also spills out of the cell and breaks up into globin and heme.

Heme is converted into unconjugated, or indirect, bilirubin which is then taken up by the liver cells and eventually secreted out with bile.

If all of a sudden, your body starts breaking down more RBCs than the liver cells can handle, the excess bilirubin stays in the blood and cause jaundice where the bilirubin deposits in the skin and the eyes, causing them to turn yellow.

Also, when there’s too much bilirubin in the bile, it can form pigmented gallstones.

Some of the bilirubin is converted to urobilin which is what gives urine that yellow color, but if there’s too much of it, the urine becomes a much darker, tea-like color.

Okay, so let’s take a closer look at these different extrinsic hemolytic anemias, starting with autoimmune hemolytic anemia where antibodies and complement are directed against RBCs, leading to their destruction.

It’s like the RBC equivalent of immune thrombocytopenic purpura, or ITP, a disorder where autoantibodies bind to the platelet receptor and cause them to be targeted by immune cells in the spleen for destruction.

In fact, some patients develop both conditions together, and that’s called Evan’s syndrome.

Based on the type of antibodies produced, autoimmune hemolytic anemia can be divided further into IgG, also called warm antibody, hemolytic anemia, and IgM hemolytic anemia, also called cold agglutinin disease.

Now, it’s important to remember the causes, since they might be the best clues for identifying autoimmune hemolytic anemia in the exams.

Warm antibody hemolytic anemia is typically seen in chronic lymphocytic leukemia, or CLL, systemic lupus erythematosus, or SLE, and with the use of antibiotics like penicillins and cephalosporins, sulfa drugs, and the antihypertensive drug, methyldopa.

Cold agglutinin disease is often seen in CLL, Waldenstrom macroglobulinemia, a rare type of malignant lymphoma, and infections like infectious mononucleosis and mycoplasma pneumoniae infections.

Next up is microangiopathic hemolytic anemia that occurs in the small blood vessels and include thrombotic thrombocytopenic purpura, or TTP, hemolytic-uremic syndrome, or HUS, and disseminated intravascular coagulation, or DIC.

In these disorders, there’s excessive clot formation so when normal RBCs flow through these blood vessels, they get banged up and damaged, leading to intravascular hemolysis.

In TTP, there’s a deficiency of ADAMTS-13, a metalloproteinase that breaks Von willebrand factor, a protein needed for the formation of clots and their adhesion to the endothelial lining.

So When there’s not enough ADAMTS-13, there’s excessive clot formation, and these clots end up damaging RBCs.

TTP can be caused by a genetic mutation or it can develop after exposure to antiplatelet medications like ticlopidine and clopidogrel, or chemotherapeutic agents like cyclosporine and gemcitabine.

In some cases it can also be associated with diseases like systemic lupus erythematosus.

Alright, moving onto HUS. Typical HUS, occurs after an infection by a shiga-toxin bacteria.

The most common is Escherichia coli, but others include shigella, and salmonella.

A high yield fact for your exams is that this often occurs in children after an episode of gastroenteritis caused by these bacteria.

The toxins they release destroys colonic epithelial cells, causing bloody diarrhea, and then enters the circulation, where it damages the endothelial cells causing massive release of von willebrand factor and excessive clot formation throughout the body.

Typical HUS has good prognosis. Now, the atypical HUS is not associated with shiga-toxin, may occur at any age, and has a relatively poor prognosis.

It is linked to a genetic mutation in factor H, a protein that controls the complement system. Without it, the complement system goes wild, causing damage to the endothelial cells and excessive clot formation.

Next up is DIC, where there is a massive overactivation of the coagulation system in response to something like sepsis or trauma.

This leads to widespread clotting, organ ischemia, and microangiopathic hemolytic anemia, while at the same time depletes platelets and clotting factors, which paradoxically, leads to bleeding.

Sources

  1. "Kaplan USMLE Step 2 CK Lecture Notes Internal Medicine" Kaplan Medical (2017)
  2. "Robbins Basic Pathology" Elsevier (2017)
  3. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  4. "Hemolytic Anemia: Evaluation and Differential Diagnosis" Am Fam Physician (2018)
  5. "Autoimmune hemolytic anemia" Hematology (2018)
  6. "Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review" Wiener klinische Wochenschrift (2008)
  7. "Hemolytic uremic syndrome" Türk Pediatri Arşivi (2015)
  8. "Haemolytic uremic syndrome: diagnosis and management" F1000Research (2019)
  9. "Management of thrombotic thrombocytopenic purpura: current perspectives" Journal of Blood Medicine (2014)
  10. "Thrombotic microangiopathies: a general approach to diagnosis and management" Canadian Medical Association Journal (2016)
  11. "Relationships between anaemia and parasitic infections in Kenyan schoolchildren: A Bayesian hierarchical modelling approach" International Journal for Parasitology (2008)